4.6 Article

The Unique Cytoplasmic Domain of Human FcγRIIIA Regulates Receptor-Mediated Function

Journal

JOURNAL OF IMMUNOLOGY
Volume 189, Issue 9, Pages 4284-4294

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1200704

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01-AR33062, P01-AR49084, P60-AR49095, P30-AR48311]

Ask authors/readers for more resources

Ligand specificity characterizes receptors for Abs and many other immune receptors, but the common use of the FcR gamma-chain as their signaling subunit challenges the concept that these receptors are functionally distinct. We hypothesized that elements for specificity might be determined by the unique cytoplasmic domain (CY) sequences of the ligand-binding alpha-chains of gamma-chain-associated receptors. Among Fc gamma receptors, a protein kinase C (PKC) phosphorylation consensus motif [ RSSTR], identified within the Fc gamma RIIIa (CD16A) CY by in silico analysis, is specifically phosphorylated by PKCs, unlike other FcRs. Phosphorylated CD16A mediates a more robust calcium flux, tyrosine phosphorylation of Syk, and proinflammatory cytokine production, whereas nonphosphorylatable CD16A is more effective at activation of the Gab2/PI3K pathway, leading to enhanced degranulation. S100A4, a specific protein-binding partner for CD16A-CY newly identified by yeast two-hybrid analysis, inhibits phosphorylation of CD16A-CY by PKC in vitro, and reduction of S100A4 levels in vivo enhances receptor phosphorylation upon cross-linking. Taken together, PKC-mediated phosphorylation of CD16A modulates distinct signaling pathways engaged by the receptor. Calcium-activated binding of S100A4 to CD16A, promoted by the initial calcium flux, attenuates the phosphorylation of CY, and, acting as a molecular switch, may both serve as a negative feedback on cytokine production pathways during sustained receptor engagement and favor a shift to degranulation, consistent with the importance of granule release following conjugate formation between CD16A(+) effector cells and target cells. This switch mechanism points to new therapeutic targets and provides a framework for understanding novel receptor polymorphisms. The Journal of Immunology, 2012, 189: 4284-4294.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available